Palo Alto, CA · Salary not listed
Posted Sep 10, 2026 · Experience not stated
Opens Delfi Diagnostics, Inc.'s own application page in a new tab, this page stays open behind it.
Vice President, People
Named on Delfi Diagnostics, Inc.'s FY2026 H-1B filings
Sign in to see their name and work email, plus a short intro note you can edit and send. You reach a person instead of dropping your resume into another online form. Not always the recruiter for this opening.
Create a free accountFiling data last recomputed Aug 9, 2026.
Sponsor score is an evidence index from 0 to 100, built from this employer's past public DOL and USCIS filings. It is not a probability that this role will sponsor you. Read how scores work.
DELFI Diagnostics, Inc. (DELFI Diagnostics) is developing next-generation, blood-based tests that are reliable, accessible and deliver a new way to help detect cancer. Employing advanced machine-learning methods to whole-genome sequencing data, the DELFI ("DNA EvaLuation of Fragments for early Interception") platform is built to address the highest-burden health challenges. DELFI Diagnostics prioritizes solutions that have the potential to save lives on a global scale, including for historically underserved populations. DELFI Diagnostics’ platform relies on fragmentomics – the discovery that cancer cells are more chaotic than normal cells and, when they die, leave behind tell-tale patterns and characteristics of cell-free DNA (cfDNA) fragments. FirstLook Lung, for individuals eligible for lung cancer screening, is DELFI Diagnostics’ first laboratory-developed screening test and can be part of routine blood work. FirstLook Lung uses millions of data points to reliably identify individuals who may have cancer detected through low-dose CT, including early stage disease with a negative predictive value of 99.8 percent. This test has not been cleared or approved by the FDA.
In our passionate pursuit to radically improve health outcomes, we serve humanity when we: